一项涉及 435,000 人的斯堪的纳维亚研究发现，没有证据表明长期使用 GLP-1 类似物与甲状腺癌风险有关。 435,000-person Scandinavian study finds no evidence linking long-term GLP-1 analogue use to thyroid cancer risk.

一项涉及超过 435,000 人的大型斯堪的纳维亚研究发现，没有证据表明长期使用 Wegovy 和 Ozempic 等 GLP-1 类似物药物会增加患甲状腺癌的风险。 A large Scandinavian study, involving over 435,000 people, has found no evidence to suggest that long-term use of GLP-1 analogue medications, such as Wegovy and Ozempic, increases the risk of thyroid cancer. 这些用于治疗糖尿病和肥胖症的药物以前曾与甲状腺肿瘤风险增加有关，但这项研究有力地证明 GLP-1 类似物与甲状腺癌风险增加无关。 These drugs, used for treating diabetes and obesity, have previously been associated with an increased risk of thyroid tumours, but this study provides strong support that GLP-1 analogues are not associated with an increased risk of thyroid cancer.